Partillion Bioscience Corp
Los Angeles, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2360 Glendon Ave, Los Angeles, CA 90064, USA
- Website
- partillion.com
- Founded
- 2020
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Triangle Biotechnology, Inc. | Chapel Hill, NC | — |
| Sansimeon, Inc. | Wilmington, DE | — |
| Neuroindx | Torrance, CA | 423490 Other Professional Equipment and Supplies Merchant Wholesalers |
| Fluent Biosciences Inc. | — | 325414 Biological Product (except Diagnostic) Manufacturing |
| Enrich Biosystems Inc. | Branford, CT | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Partillion Bioscience Corp, a Los Angeles-based for-profit manufacturer of biotech reagents and discovery tools, operates exclusively as a federal grant recipient (100% prime awards) with the National Institutes of Health, advancing nanovial-based cell screening and sequencing technologies for therapeutic discovery. The company holds no federal contracts and does not operate through contracting vehicles; all federal support flows through NIH Small Business Innovation Research (SBIR) and project grant awards totaling $11.5 million across ten grants since 2021.
Partillion's federal grant portfolio centers on nanovial technology — engineered hydrogel microcontainers that compartmentalize single cells and cell pairs for high-throughput functional screening compatible with standard sequencing and flow cytometry equipment. The company acts as prime recipient on all awards, with no subrecipient relationships reflected in the source data. Recent representative work includes a $979,071 Phase II award from the National Institute of General Medical Sciences (CFDA 93.859) granted September 1, 2026, to develop nanovial kits for large-scale cell-cell interaction sequencing with applications in antibody discovery and innate immunity studies (performance through August 31, 2028); a $306,865 Phase I SBIR award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855) granted July 16, 2026, for multiplexed monoclonal antibody discovery using streptavidin-antigen nanovial formulations and multiepitope sequencing readouts (completion June 30, 2027); an April 1, 2025 Phase II NIAD grant for scaling function-first antibody discovery using memory B cells with 10× throughput enhancement; and an August 1, 2023 award from NIAD for developing high-dynamic-range nanovial assays measuring five secreted cytokines from single cells to support polyfunctional T cell sorting and immune screening.
Customer concentration is heavily concentrated within NIH. The National Institute of General Medical Sciences and the National Institute of Allergy and Infectious Diseases account for nine of ten awards (90% coverage), with NIGMS holding six awards and NIAD holding three; the National Science Foundation Division of Industrial Innovation holds one award. Three awards reach ultimate completion within the next twenty-four months, representing recompete exposure. The company's award activity shows episodic clustering — five awards in 2021, then a two-year gap before resuming in 2023 — with recent acceleration in 2025 and 2026 reflecting growing NIH investment in the nanovial platform for cell therapy screening, CAR-T engineering, and antibody characterization workflows.
Quick answers
Is Partillion Bioscience Corp registered in SAM.gov?
Yes. Partillion Bioscience Corp's SAM.gov registration is active through February 26, 2027.
What is Partillion Bioscience Corp's CAGE code?
Partillion Bioscience Corp's CAGE code is 8KK41, and its Unique Entity ID (UEI) is WMNNPP5BWQM5.
What is Partillion Bioscience Corp's most recent federal award?
Partillion Bioscience Corp's most recent federal grant award is Nanovial kits for large-scale cell-cell interaction sequencing (R44GM165220), from National Institute of General Medical Sciences (NIH), on September 1, 2026.
On GovTribe
See Partillion Bioscience Corp's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors